APVO · Aptevo Therapeutics Inc.
$2.94
-0.46 (-13.53%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“When considered in aggregate, these factors raise substantial doubt about our ability to continue as a going concern for the one-year period from the date of issuance of these financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.30M
Shares
1.80M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.11M
-74.7%
FY2022
Net Income
-$25.97M
-7.6%
FY2025
Gross Margin
38.54%
-12.8pp
FY2019
Operating Margin
-919.75%
-745.6pp
FY2022
Diluted EPS
-$87.27
+99.7%
FY2025
Operating Cash Flow
-$25.59M
-7.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | $3.11M | $12.29M | $4.31M | $32.42M | $23.07M | $14.66M | $9.99M | $33.6M | |
| — | — | — | — | — | — | — | $19.93M | $11.21M | $5.01M | $12.47M | $16.93M | |
| — | — | — | — | — | — | — | $12.5M | $11.85M | $9.65M | -$2.48M | $16.67M | |
| — | — | — | — | — | — | — | 38.54% | 51.39% | 65.82% | -24.86% | 49.61% | |
| $15.2M | $14.54M | $14.38M | $17.11M | $17.88M | $18.99M | $17.85M | $24.76M | $35.39M | $29.02M | $29.12M | $34.73M | |
| $11.69M | $11.77M | $10.22M | $11.77M | $13.87M | $14.7M | $13.95M | $16.2M | — | — | — | — | |
| — | — | — | — | — | — | — | $25.34M | $28.13M | $34.58M | $36.16M | $43.04M | |
| — | — | — | — | — | — | — | $800K | $800K | $800K | $800K | $3.4M | |
| — | $240K | $352K | $567K | $901K | $1.14M | $1.41M | $2.24M | $2.39M | $3.13M | $3.36M | $2.91M | |
| -$26.89M | -$26.31M | -$24.6M | -$28.88M | -$28.64M | -$21.4M | -$27.49M | -$40.96M | -$51.67M | -$53.95M | -$138.77M | -$61.1M | |
| — | — | — | — | -919.75% | -174.1% | -638.06% | -126.33% | -223.98% | -368.05% | -1389.81% | -181.84% | |
| — | -$26.07M | -$24.25M | -$28.31M | -$27.74M | -$20.26M | -$26.09M | -$38.73M | -$49.28M | -$50.82M | -$135.41M | -$58.19M | |
| $478K | $345K | $472K | $578K | -$4.03M | -$8.01M | -$1.33M | -$2.1M | -$2.02M | -$1.94M | -$810K | -$237K | |
| — | -$25.97M | -$24.13M | -$18.65M | $7.01M | -$29.41M | -$30.92M | -$43.06M | -$53.69M | -$55.89M | -$139.58M | -$61.34M | |
| — | $0 | — | — | — | — | — | — | — | -$23.3M | -$19.69M | -$2.02M | |
| -$26.41M | -$25.97M | -$24.13M | -$17.41M | $8.03M | -$28.46M | -$17.75M | -$40.45M | -$53.69M | $6.97M | -$112.42M | -$59.32M | |
| — | — | — | — | 257.77% | -231.51% | -411.93% | -124.75% | -232.75% | 47.57% | -1125.84% | -176.53% | |
| -$28.08M | -$27.54M | -$24.13M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | -$40.45M | -$53.58M | $6.9M | -$112.45M | -$59.32M | |
| USD/shares | — | -$87.27 | -$31,460.23 | -$834,058.80 | $920,145.60 | -$3,557,505.60 | — | — | — | — | — | — |
| USD/shares | — | -$87.27 | -$31,460.23 | -$834,058.80 | $920,145.60 | -$3,557,505.60 | — | — | — | — | — | — |
| shares | — | 315.54K | 767 | 20.875 | 8.7024 | 7.9988 | 5.7858 | 4.9772 | 2.7422 | 2.6002 | 2.4667 | 2.4655 |
| shares | — | 315.54K | 767 | 20.875 | 8.7069 | 7.9988 | 5.7858 | 4.9772 | 2.7422 | 2.6002 | 2.4667 | 2.4655 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.60×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 159 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
1671584
CUSIP
03835L702
13F (30d)
10 filings
10 filers
Visit website
Investor relations